Logo image of SRCL

Stericycle Inc (SRCL) Stock Fundamental Analysis

USA - NASDAQ:SRCL - US8589121081 - Common Stock

61.98 USD
+0.51 (+0.83%)
Last: 11/1/2024, 8:00:01 PM
61.98 USD
0 (0%)
After Hours: 11/1/2024, 8:00:01 PM
Fundamental Rating

3

Overall SRCL gets a fundamental rating of 3 out of 10. We evaluated SRCL against 84 industry peers in the Commercial Services & Supplies industry. SRCL has a medium profitability rating, but doesn't score so well on its financial health evaluation. SRCL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

SRCL had positive earnings in the past year.
In the past year SRCL had a positive cash flow from operations.
In the past 5 years SRCL reported 4 times negative net income.
Each year in the past 5 years SRCL had a positive operating cash flow.
SRCL Yearly Net Income VS EBIT VS OCF VS FCFSRCL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M

1.2 Ratios

SRCL has a Return On Assets (0.66%) which is in line with its industry peers.
SRCL has a Return On Equity (1.42%) which is in line with its industry peers.
With a Return On Invested Capital value of 3.62%, SRCL perfoms like the industry average, outperforming 42.35% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for SRCL is significantly below the industry average of 10.21%.
Industry RankSector Rank
ROA 0.66%
ROE 1.42%
ROIC 3.62%
ROA(3y)0.05%
ROA(5y)-1.25%
ROE(3y)0.1%
ROE(5y)-3.39%
ROIC(3y)3.93%
ROIC(5y)3.93%
SRCL Yearly ROA, ROE, ROICSRCL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5 -5 -10

1.3 Margins

Looking at the Profit Margin, with a value of 1.37%, SRCL is in line with its industry, outperforming 47.06% of the companies in the same industry.
SRCL has a Operating Margin of 8.35%. This is in the better half of the industry: SRCL outperforms 61.18% of its industry peers.
In the last couple of years the Operating Margin of SRCL has declined.
Looking at the Gross Margin, with a value of 38.58%, SRCL is in the better half of the industry, outperforming 65.88% of the companies in the same industry.
In the last couple of years the Gross Margin of SRCL has remained more or less at the same level.
Industry RankSector Rank
OM 8.35%
PM (TTM) 1.37%
GM 38.58%
OM growth 3Y1.79%
OM growth 5Y-5.31%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.25%
GM growth 5Y-1.05%
SRCL Yearly Profit, Operating, Gross MarginsSRCL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20 30 40

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SRCL is destroying value.
Compared to 1 year ago, SRCL has more shares outstanding
SRCL has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SRCL has been reduced compared to a year ago.
SRCL Yearly Shares OutstandingSRCL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
SRCL Yearly Total Debt VS Total AssetsSRCL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B

2.2 Solvency

An Altman-Z score of 2.17 indicates that SRCL is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.17, SRCL is in line with its industry, outperforming 50.59% of the companies in the same industry.
SRCL has a Debt/Equity ratio of 0.55. This is a neutral value indicating SRCL is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.55, SRCL perfoms like the industry average, outperforming 45.88% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF N/A
Altman-Z 2.17
ROIC/WACC0.45
WACC7.97%
SRCL Yearly LT Debt VS Equity VS FCFSRCL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B

2.3 Liquidity

SRCL has a Current Ratio of 1.13. This is a normal value and indicates that SRCL is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.13, SRCL is doing worse than 74.12% of the companies in the same industry.
SRCL has a Quick Ratio of 1.13. This is a normal value and indicates that SRCL is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.13, SRCL is doing worse than 63.53% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.13
Quick Ratio 1.13
SRCL Yearly Current Assets VS Current LiabilitesSRCL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

4

3. Growth

3.1 Past

SRCL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.74%, which is quite good.
SRCL shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -15.70% yearly.
The Revenue has decreased by -1.68% in the past year.
The Revenue has been decreasing by -5.27% on average over the past years.
EPS 1Y (TTM)9.74%
EPS 3Y-5.65%
EPS 5Y-15.7%
EPS Q2Q%23.26%
Revenue 1Y (TTM)-1.68%
Revenue growth 3Y-0.2%
Revenue growth 5Y-5.27%
Sales Q2Q%-0.78%

3.2 Future

Based on estimates for the next years, SRCL will show a very strong growth in Earnings Per Share. The EPS will grow by 21.37% on average per year.
SRCL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.90% yearly.
EPS Next Y22.51%
EPS Next 2Y22.71%
EPS Next 3Y25.13%
EPS Next 5Y21.37%
Revenue Next Year2.13%
Revenue Next 2Y2.67%
Revenue Next 3Y3.39%
Revenue Next 5Y3.9%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SRCL Yearly Revenue VS EstimatesSRCL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B
SRCL Yearly EPS VS EstimatesSRCL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1 2 3 4

3

4. Valuation

4.1 Price/Earnings Ratio

SRCL is valuated quite expensively with a Price/Earnings ratio of 28.96.
Compared to the rest of the industry, the Price/Earnings ratio of SRCL is on the same level as its industry peers.
Compared to an average S&P500 Price/Earnings ratio of 27.70, SRCL is valued at the same level.
A Price/Forward Earnings ratio of 21.78 indicates a rather expensive valuation of SRCL.
SRCL's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. SRCL is cheaper than 67.06% of the companies in the same industry.
SRCL's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.15.
Industry RankSector Rank
PE 28.96
Fwd PE 21.78
SRCL Price Earnings VS Forward Price EarningsSRCL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

SRCL's Enterprise Value to EBITDA ratio is in line with the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 16.43
SRCL Per share dataSRCL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

SRCL's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
SRCL's earnings are expected to grow with 25.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.29
PEG (5Y)N/A
EPS Next 2Y22.71%
EPS Next 3Y25.13%

0

5. Dividend

5.1 Amount

SRCL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

Stericycle Inc

NASDAQ:SRCL (11/1/2024, 8:00:01 PM)

After market: 61.98 0 (0%)

61.98

+0.51 (+0.83%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryCommercial Services & Supplies
Earnings (Last)11-01 2024-11-01/bmo
Earnings (Next)N/A N/A
Inst Owners90.4%
Inst Owner Change0%
Ins Owners1.15%
Ins Owner Change0%
Market Cap5.75B
Analysts71.43
Price Target63.01 (1.66%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.59%
Min EPS beat(2)-13.77%
Max EPS beat(2)0.6%
EPS beat(4)2
Avg EPS beat(4)-1.75%
Min EPS beat(4)-13.77%
Max EPS beat(4)13.33%
EPS beat(8)4
Avg EPS beat(8)-0.41%
EPS beat(12)4
Avg EPS beat(12)-7.09%
EPS beat(16)6
Avg EPS beat(16)-3.85%
Revenue beat(2)0
Avg Revenue beat(2)-3.52%
Min Revenue beat(2)-3.63%
Max Revenue beat(2)-3.41%
Revenue beat(4)0
Avg Revenue beat(4)-3.88%
Min Revenue beat(4)-5.65%
Max Revenue beat(4)-2.85%
Revenue beat(8)2
Avg Revenue beat(8)-3.12%
Revenue beat(12)2
Avg Revenue beat(12)-3.07%
Revenue beat(16)3
Avg Revenue beat(16)-2.6%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.75%
EPS NY rev (1m)2.76%
EPS NY rev (3m)-2.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.1%
Revenue NY rev (1m)1.31%
Revenue NY rev (3m)0.73%
Valuation
Industry RankSector Rank
PE 28.96
Fwd PE 21.78
P/S 2.19
P/FCF N/A
P/OCF 73.87
P/B 2.27
P/tB N/A
EV/EBITDA 16.43
EPS(TTM)2.14
EY3.45%
EPS(NY)2.85
Fwd EY4.59%
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)0.84
OCFY1.35%
SpS28.35
BVpS27.27
TBVpS-9.24
PEG (NY)1.29
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.66%
ROE 1.42%
ROCE 4.58%
ROIC 3.62%
ROICexc 3.65%
ROICexgc 12.66%
OM 8.35%
PM (TTM) 1.37%
GM 38.58%
FCFM N/A
ROA(3y)0.05%
ROA(5y)-1.25%
ROE(3y)0.1%
ROE(5y)-3.39%
ROIC(3y)3.93%
ROIC(5y)3.93%
ROICexc(3y)3.97%
ROICexc(5y)3.96%
ROICexgc(3y)17.82%
ROICexgc(5y)18.44%
ROCE(3y)4.98%
ROCE(5y)4.97%
ROICexcg growth 3Y-5.76%
ROICexcg growth 5Y-15.82%
ROICexc growth 3Y3.26%
ROICexc growth 5Y-6.36%
OM growth 3Y1.79%
OM growth 5Y-5.31%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.25%
GM growth 5Y-1.05%
F-Score7
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF N/A
Debt/EBITDA 3.21
Cap/Depr 68.63%
Cap/Sales 5.59%
Interest Coverage 2.63
Cash Conversion 17.95%
Profit Quality N/A
Current Ratio 1.13
Quick Ratio 1.13
Altman-Z 2.17
F-Score7
WACC7.97%
ROIC/WACC0.45
Cap/Depr(3y)56.57%
Cap/Depr(5y)58.42%
Cap/Sales(3y)4.75%
Cap/Sales(5y)4.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.74%
EPS 3Y-5.65%
EPS 5Y-15.7%
EPS Q2Q%23.26%
EPS Next Y22.51%
EPS Next 2Y22.71%
EPS Next 3Y25.13%
EPS Next 5Y21.37%
Revenue 1Y (TTM)-1.68%
Revenue growth 3Y-0.2%
Revenue growth 5Y-5.27%
Sales Q2Q%-0.78%
Revenue Next Year2.13%
Revenue Next 2Y2.67%
Revenue Next 3Y3.39%
Revenue Next 5Y3.9%
EBIT growth 1Y-1.39%
EBIT growth 3Y1.59%
EBIT growth 5Y-10.3%
EBIT Next Year71.62%
EBIT Next 3Y32.09%
EBIT Next 5Y23.1%
FCF growth 1Y-997.4%
FCF growth 3Y-35.15%
FCF growth 5Y26.26%
OCF growth 1Y-42.25%
OCF growth 3Y-22.87%
OCF growth 5Y7.99%